{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-175601","form_type":"8-K/A","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.521209+00:00","generated_at":"2026-06-25T01:17:34.972769+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cogent closes upsized $172.6M public offering of common stock and pre-funded warrants","bullets":["Gross proceeds ~$172.6M from 17,899,698 shares at $8.25 and 3,030,302 pre-funded warrants at $8.24.","Net proceeds to fund development and commercial activities for bezuclastinib and other candidates.","Underwriters exercised in full their option to purchase 2,730,000 additional shares.","Pre-funded warrants exercisable at $0.01 per share, subject to 9.99% beneficial ownership limitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-175601","json":"https://secwatch.observer/filing/0001193125-22-175601.json","markdown":"https://secwatch.observer/filing/0001193125-22-175601.md","text":"https://secwatch.observer/filing/0001193125-22-175601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312522175601/0001193125-22-175601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312522175601/d357403d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:17:34.972769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}